Does HRMY pay a dividend and is it safe?

Harmony Biosciences Holdings Inc. (HRMY) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / HRMY / dividends

VERA (31) HCM (34) XNCR (47) AUPH (74) ⌘ Pro Terminal →

Harmony Biosciences Holdings Inc. (HRMY) Dividend Safety Gauge & 10-Year DRIP Compounder

$37.91 -2.19% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $37.85

Harmony Biosciences Holdings Inc. (HRMY) earns a Roarable Rating of A (Strong Buy) with 86/100 RQD Confidence. High-quality cash engine (77% profit margin, 63% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 86/100 (A) historically ranked in the Top 5% of excess returns over the next 90 days (+9.2% avg 90D alpha vs SPY • 73.2% hit rate) →

ROARABLE A • STRONG BUY Cap $2.26B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HRMY Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HRMY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) is rated A (Strong Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 86/100 at a spot price of $37.91 (-2.19% 1D, market cap $2.26B). Pillar breakdown: Fundamental Cash Engine 20/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 18/20, and SEC Balance-Sheet Forensics 19/20. Across 1016 tracked Health Care issuers, HRMY ranks #4 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HRMY compare to VERA and HCM in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HRMY carries a Roarable A (86/100 RQD), trailing P/E of 14.2x, gross margin of 77.2%, and ROIC of 63.0%. By comparison, VERA (Vera Therapeutics Inc. (Class A)) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $2.23B) and HCM (HUTCHMED (China) Limited) posts a E grade (34/100 RQD, P/E 5.2x, ROIC -2.5%, cap $2.29B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while HRMY leads on capital efficiency (63.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HRMY?

▼

Per HRMY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001802665), Harmony Biosciences Holdings Inc. generated $868.5M in revenue (+21.5% YoY), $158.7M in net income, and $347.9M in free cash flow against $1.27B in total assets and $143.7M in total debt. Key quantitative strengths: Strong cash generator (77% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $37.85 (-0.15%)🧬 Cannibal Buyback (-3.20% YoY Shares)⚙️ Cash Engine: 20/20 (A+) • 40.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 86/100 (A) historically ranked in the Top 5% of excess returns over the next 90 days (+9.2% avg 90D alpha vs SPY • 73.2% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSTRONG BUY • A

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw A- · Rk A

Each axis scored 0–20

12M PRICE TARGET CONE+12.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HRMY)Realized 20D OHLCV Swing Band: ±8.2%

Deterministic 5-Pillar Attribution (86/100 Composite)

🔍 WHY HRMY SCORES 86/100 (A) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+20/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 40.1% FCF Margin ($347.9M FCF) & 77.2% Gross Margin

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+19/20 pts (22% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-3.20% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning11/20 pts (-9 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-9 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade A-$37.03+4.5% Next Q

Q2 (-2Q)

Grade A-$38.70-1.9% Next Q

Q3 (-1Q)

Grade A$37.95-0.1% Next Q

Current

Grade A$37.91+9.2% Hist 90D α

Trajectory: A- (78) → A (86)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the HRMY Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 86/100 (A) score, HRMY faces multiple-compression risk if 14.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-3.20% YoY Shares) — any gross margin slip below 74.7% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($39.78) or 200D SMA ($34.71) invalidates the momentum regime and cuts Target Base ($42.69) toward Bear Floor ($31.09).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HRMY• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “HRMY Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 86%NO 14%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (13.6% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $35,792

Est. Year-10 Shareholder Yield: $644/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.4K

Yr 1

$12.9K

Yr 2

$14.7K

Yr 3

$16.7K

Yr 4

$18.9K

Yr 5

$21.5K

Yr 6

$24.4K

Yr 7

$27.7K

Yr 8

$31.5K

Yr 9

$35.8K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in HRMY & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on HRMY and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HRMY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +16.32%📐 HORIZONTAL RANGE

2026-11-03O $38.59H $38.76L $37.91C $37.91VOL 871.5K

RES: $48.09SUP: $33.47SMA50: $39.78SMA200: $34.71

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HRMY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HRMY Butterfly Map → + Track HRMY →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

6.0%/yr Implied 5Y Growth

vs. +21.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HRMY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HRMY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HRMY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HRMY)

Health Care Rank #4 of 1016 ⚔️ VERA vs HRMY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HRMY vs. VERA, HCM, XNCR, AUPH)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Harmony Biosciences Holdings Inc. (HRMY) ranks #4 by composite RQD confidence (86/100, grade A) and #235 by equity capitalization ($2.26B). Within this direct 5-issuer industry benchmark cohort, HCM leads on earnings valuation at 5.2x trailing P/E, while HRMY leads on capital efficiency and profitability with 63.0% ROIC and 77.2% gross margin. HRMY currently leads its immediate peer cohort in composite quantitative strength at 86/100 (A).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HRMY ACTIVE Harmony Biosciences Holdings Inc.	A	86/100	14.2x	77.2%	63.0%	-2.19%	$2.26B	Benchmark Subject
VERA Vera Therapeutics Inc. (Class A)	E	31/100	—	—	-35.0%	-2.36%	$2.23B	/vera-vs-hrmy →
HCM HUTCHMED (China) Limited	E	34/100	5.2x	—	-2.5%	+0.91%	$2.29B	/hcm-vs-hrmy →
XNCR Xencor Inc.	D	47/100	—	—	-21.3%	-0.54%	$2.22B	/xncr-vs-hrmy →
AUPH Aurinia Pharmaceuticals Inc	B	74/100	8.0x	88.5%	16.5%	-3.06%	$2.22B	/auph-vs-hrmy →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001802665

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Harmony Biosciences Holdings Inc. (HRMY) reported GAAP revenue of $868.5M (+21.5% vs. FY2024 revenue of $714.7M , and +49.2% cumulative change since FY2023) , GAAP net income of $158.7M, operating cash flow of $348.2M, and free cash flow of $347.9M (+59.1% YoY). On the balance sheet, HRMY closed FY2025 with $1.27B in total assets against $143.7M in total debt (Altman Z-Score: 5.38, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$868.5M	$158.7M	$348.2M	$347.9M	$1.27B	$143.7M
FY2024 (FY)	2024-12-31	$714.7M	$145.5M	$219.8M	$218.7M	$999.2M	$163.0M
FY2023 (FY)	2023-12-31	$582.0M	$128.9M	$219.4M	$219.4M	—	—

3. HRMY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HRMY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does HRMY compare to VERA and HCM in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for HRMY?

Where is HRMY trading relative to its 50-day, 200-day, and 52-week technical levels?

HRMY last traded at $37.91 (-2.19% on volume of 994,027 shares), positioning the stock -4.70% below its 50-day simple moving average ($39.78) and +9.22% above its 200-day simple moving average ($34.71). Across its 52-week range of $25.90 to $43.49, HRMY sits at the 68.3% percentile with a 14-day RSI of 51.1 (NEUTRAL RANGE) and an implied next-earnings move of ±8.2% ($34.80 to $41.02).

Direct Sub-Reports: HRMY RQD Cockpit HRMY 12M Forecast HRMY Earnings & Move HRMY Dividends & DRIP HRMY Insiders & 13F HRMY Whale Options HRMY Profit Sankey HRMY News & Why

ROARABLE RATING BRIEF • RQD 86/100 (A) ✓ STAGE-C NUMBER FIREWALL VERIFIED

HRMY — Harmony Biosciences Holdings Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:26:16Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

HRMY scores 86 out of 100, a letter grade of A, with the verdict label "Roarable Strong Buy — Excellent Cash & Whale Support." The five pillars are: Fundamental Cash Engine at 20/20 (ROIC 63%; FCF yield 15.48%), Whale 13F Flow at 11/20 (institutional accumulation and options positioning), Insider Conviction at 19/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 18/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 18/20 (Altman Z 5.38; Piotroski F 9/9; Debt/Equity 0.17). For a prospective investor, the strongest pillar is cash generation, which the rating treats as maximal. The weakest pillar is institutional flow at 11/20, meaning the rating sees less supportive 13F accumulation than it sees in cash economics. Insider conviction and forensic balance sheet metrics are both high, suggesting the rating finds limited financial-distress risk. Valuation tradeoffs are visible in the market data: a P/E (TTM) of 14.2 and a forward P/E of 11.9 imply the market is not pricing in the full cash profile, but an FCF yield of 15.48% is high in absolute terms. Upside drivers implied by the rating include continued cash conversion; the main sensitivities are the institutional flow gap and the sector-level beta sensitivity. This is an analytical summary of the data, not personalized advice.

2. Business Model, Unit Margins & SEC Financial Trajectory

Harmony Biosciences Holdings Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. It operates with a market capitalization of $2.2B. —

Revenue rose from $582.0M (FY 2023) to $868.5M (FY 2025), and net income from $128.9M to $158.7M. Reported margins are a gross margin of 77.2%, operating margin of 24%, and net margin of 18.3%, with ROIC of 63%. The Altman Z-Score is 5.38 and the Piotroski F-Score is 9/9, . Per the same source, Debt/Equity is 0.17, and cash ($752.5M) exceeds debt ($143.7M) for FY 2025.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: Cash generation is exceptional, with FY 2025 FCF of $347.9M, an FCF yield of 15.48%, and ROIC of 63%. With Fundamental Cash Engine at 20/20 (ROIC 63.0%, FCF yield 15.48%) and Institutional Whale Flow at 11/20, sustained execution supports upside toward the top of the $25.90 – $43.49 52-week range.
🐻 Primary Bear Case: A pending patent ruling and a CEO transition are flagged in the news feed, and institutional flow scores only 11/20. Investors must weigh 14.2x trailing P/E and 7.8x EV/EBITDA against 24.0% operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

For a prospective investor, the second-order items the source does raise are the leadership transition and the patent ruling referenced in the news feed; their timing and magnitude are not resolved by the data.

Key Question #1: What are the terms and timing of the CEO transition referenced in the news feed, and who succeeds the outgoing CEO?
Key Question #2: What is the scope and expected timing of the patent ruling referenced by Seeking Alpha, and how much of revenue depends on the affected product?
Key Question #3: What explains the gap between FY 2025 cash of $752.5M and the reported FCF trajectory, and what is EPS for FY 2024 and FY 2025 (reported as N/A)?

HRMY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Harmony Biosciences Holdings Inc. (HRMY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to HRMY Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 20h ago

Harmony Biosciences Holdings, Inc. (HRMY) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Harmony Biosciences Holdings Inc. (HRMY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investor's Business Daily • 23h ago

Harmony Bio CEO Plans His Exit, And Shares Take An Unharmonious Hit

Investor's Business Daily report covering Harmony Biosciences Holdings Inc. (HRMY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Motley Fool • 1d ago

Why Harmony Biosciences Stock Got Mashed on Monday

The Motley Fool report covering Harmony Biosciences Holdings Inc. (HRMY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Harmony Biosciences (HRMY) Stock Looks Below Fair Value As Shares Rose 48%

Yahoo Finance report covering Harmony Biosciences Holdings Inc. (HRMY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Harmony Biosciences: A Cash Machine With A Patent Ruling Hanging Over It (NASDAQ:HRMY)

Seeking Alpha report covering Harmony Biosciences Holdings Inc. (HRMY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GuruFocus • 1d ago

Harmony Biosciences (HRMY) Names Peter Anastasiou as CEO, Market Reacts

GuruFocus report covering Harmony Biosciences Holdings Inc. (HRMY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?

Yahoo Finance report covering Harmony Biosciences Holdings Inc. (HRMY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

BlackRock reports a passive stake in Harmony Biosciences (HRMY), with an iShares ETF holding over 5%.

Stock Titan report covering Harmony Biosciences Holdings Inc. (HRMY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HRMY Bull vs. Bear Conversation Board — What's Your Call at $37.91?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HRMY 🐻 33% BEARISH CONVICTION

DE DeepValue_CFA Institutional Buy-Side 🐂 BULLISH 🎯 Target: $49.23 (+27.0%)

📌 Pinned Debate

Cash generation is exceptional, with FY 2025 FCF of $347.9M, an FCF yield of 15.48%, and ROIC of 63%.

Cash generation is exceptional, with FY 2025 FCF of $347.9M, an FCF yield of 15.48%, and ROIC of 63%.. When you look under the hood at HRMY, Fundamental Cash Engine is 20/20 with 77.2% gross margins and 63.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (11/20) has been quietly accumulating below $43.49. My 12M target is $49.23.

EarningsSniper 🐂 BULL

@MultipleCompression Shorting a 11/20 institutional whale-flow stock at $38.76 is dangerous when funds are rotating into Health Care.

MU MultipleCompression Valuation Discipline 🐻 BEARISH 🎯 Target: $29.46 (-24.0%)

Spot @ $38.76

A pending patent ruling and a CEO transition are flagged in the news feed, and institutional flow scores only 11/20.

Here is the bear case nobody on the bull side wants to address on HRMY: A pending patent ruling and a CEO transition are flagged in the news feed, and institutional flow scores only 11/20.. At 14.2x trailing P/E, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.